-
Optimizing Healthcare Systems in the MENA Region: Insights From Tailored Reimbursement for Innovative and Generic Essential Remedies (TRIGER) Meetings in Saudi Arabia and Algeria
Sep 9, 2025, 16:22 PM -
Economic Evaluation of Bispecific Antibodies in Europe: A Systematic Review
Sep 9, 2025, 16:22 PM -
Standardizing Healthtech Evidence to Meet NICE Expectations
Sep 9, 2025, 16:22 PM -
Involving Women With Lived Experience of Pelvic Organ Prolapse in Designing and Refining the Economic Components of a Health Technology Assessment
Sep 9, 2025, 16:22 PM -
A Contemporary Approach to Determining Cancer Patients Healthcare Resources Utilization
Sep 9, 2025, 16:22 PM -
Adapting HTA Frameworks for Precision Medicine: Methodological Advances in the UK and EU4
Sep 9, 2025, 16:22 PM -
Social Determinants of Health Affecting Response to Opioid Addiction Treatment
Sep 9, 2025, 16:22 PM -
Years of Life Lost and Productivity TB1 SY2 Costs Due to Premature Cancer-Related Mortality in Morocco
Sep 9, 2025, 16:22 PM -
Financial Impact of Increased Emergency Service Utilization in a Colombian Health Insurer: Evidence From the Caribbean Region
Sep 9, 2025, 16:22 PM -
Cardiovascular Disease Risk-Reducing Strategies in Qatari Diabetes Patients: A Cost-Effectiveness Study
Sep 9, 2025, 16:22 PM -
Health Economic Assessment of Using Single-Operator Direct Visualization Cholangioscopy in the Management of Complex Bile Duct Stones in Saudi Arabia
Sep 9, 2025, 16:22 PM -
Use of the ESMO-Magnitude of Clinical Benefit Scale to Guide HTA Recommendations on Coverage and Reimbursement for Cancer Medicines in Ireland: A Retrospective Analysis
Sep 9, 2025, 16:22 PM -
Are We Measuring What Matters in Postpartum Depression Trials?
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Secukinumab for Moderate to Severe Hidradenitis Suppurativa in Portugal
Sep 9, 2025, 16:22 PM -
COPD-Asthma Overlap in Brazilian Private Healthcare: Clinical Profiles and Outcomes from a Real-World Analysis
Sep 9, 2025, 16:22 PM -
Complement C5 Inhibitor (Anti-C5) and Neonatal Fc Receptor Antagonist Anti-FcRn in Myasthenia Gravis at University Public Hospitals of Paris, France (AP-HP): What Is the Market Share of These New Treatments?
Sep 9, 2025, 16:22 PM -
Burden of Disease in Hereditary Transthyretin Amyloidosis With Polyneuropathy in Spain
Sep 9, 2025, 16:22 PM -
Harmonization of Drug Policy and Regulation Across Europe: A Comparison Between the European Medicines Agency and the European HTA Regulation
Sep 9, 2025, 16:22 PM -
The Role of Lifestyle in the Development of Fertility Issues
Sep 9, 2025, 16:22 PM -
Towards Quantifying the Impact of Hypofractionation vs. Standard Radiotherapy Treatment Regimens for Cancer on Costs Workflow and the Environment
Sep 9, 2025, 16:22 PM